10x Genomics (NASDAQ: TXG) CEO sells 15,000 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

10x Genomics, Inc. CEO Serge Saxonov reported open‑market sales of 15,000 shares of Class A Common Stock. He sold 10,000 shares on March 23, 2026 at a weighted average price of $19.1297 per share and 5,000 shares on March 24, 2026 at a weighted average price of $19.5223 per share.

The filing states these transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 29, 2025. After the sales, he directly holds 1,172,273 shares of Class A Common Stock and also has significant additional indirect and Class B holdings held through various trusts where he serves as trustee, with each Class B share convertible into one Class A share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxonov Serge

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/23/2026		S(1)		10,000	D	$19.1297(2)	1,177,273(3)	D
Class A Common Stock	03/24/2026		S(1)		5,000	D	$19.5223(4)	1,172,273	D
Class A Common Stock								27	I	See footnote(5)
Class A Common Stock								213,250	I	See footnote(6)
Class A Common Stock								71,644(3)	I	See footnote(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Class B Common Stock	(8)							(8)	(8)	Class A Common Stock	1,100,927		1,100,927(9)	D
Class B Common Stock	(8)							(8)	(8)	Class A Common Stock	180,938		180,938(9)	I	See footnote(10)
Class B Common Stock	(8)							(8)	(8)	Class A Common Stock	1,750,000		1,750,000	I	See footnote(11)

Explanation of Responses:

1. The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

2. This transaction was executed in multiple trades at prices ranging from $18.78 to $19.41, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Reflects the transfer by the Reporting Person of 13,644 shares of Class A Common Stock to the Y/S Pot Trust on March 3, 2026.

4. This transaction was executed in multiple trades at prices ranging from $19.49 to $19.59, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

6. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

7. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

8. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

9. Reflects the transfer by the Reporting Person of 91,113 shares of Class B Common Stock to the Sirius Trust on March 3, 2026.

10. The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee.

11. 250,000 shares are held by each of Polaris 2018 Irrevocable Trust, Antares 2018 Irrevocable Trust, Arcturus 2018 Irrevocable Trust, FLY 2018 Irrevocable Trust, LY 2018 Irrevocable Trust, MS 2018 Irrevocable Trust and NS 2018 Irrevocable Trust, of which the Reporting Person is the sole trustee.

	/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did 10x Genomics (TXG) CEO Serge Saxonov report?

Serge Saxonov reported selling 15,000 shares of Class A Common Stock. He sold 10,000 shares on March 23, 2026 and 5,000 shares on March 24, 2026 in open‑market transactions at weighted average prices around $19 per share.

Were Serge Saxonov’s 10x Genomics (TXG) share sales pre‑planned under a Rule 10b5‑1 plan?

Yes, the filing states the sales were under a Rule 10b5‑1 trading plan. The plan was adopted on November 29, 2025, indicating the sales were pre‑arranged rather than newly decided at the time of execution.

How many 10x Genomics (TXG) shares does CEO Serge Saxonov hold after the reported sales?

After the transactions, Serge Saxonov directly holds 1,172,273 Class A shares. In addition, he has indirect and Class B holdings through multiple trusts where he serves as trustee, and each Class B share is convertible into one Class A share.

What prices did Serge Saxonov receive for his 10x Genomics (TXG) share sales?

The reported weighted average sale prices were $19.1297 and $19.5223 per share. The filing notes each day’s sale was executed in multiple trades within narrower price ranges, with full trade details available upon request.

How are Serge Saxonov’s trust holdings in 10x Genomics (TXG) structured?

Many shares are held in various trusts where Serge Saxonov serves as trustee. These include the Andromeda Trust, Y/S Descendants' Trust, Y/S Pot Trust, Sirius Trust and several 2018 irrevocable trusts, reflecting substantial additional indirect and Class B holdings.

What is the significance of 10x Genomics (TXG) Class B shares in Serge Saxonov’s holdings?

Each Class B share is convertible into one Class A share with no expiration date. Class B shares also convert automatically to Class A upon transfer, subject to exceptions and conditions in the company’s Amended and Restated Certificate of Incorporation.